November 21, 2016 Press release - Regulatory Targovax ASA: Registration of share capital increase following exercise of employee options
November 21, 2016 Press release - Regulatory Targovax ASA: Exercise of employee share options in Targovax ASA
November 18, 2016 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insider
November 10, 2016 Press release - Regulatory Targovax granted European Patent for ONCOS platform lead product, ONCOS-102
November 8, 2016 Press release - Regulatory Targovax ASA: Invitation to third quarter 2016 results presentation Thursday 17 November
November 4, 2016 Press release - Regulatory Resolutions to increase the share capital in Targovax ASA in relation to exercise of employee options and settlement of restricted stock units
November 2, 2016 Press release - Non-regulatory Targovax announces appointment of Oystein Soug as CEO
October 21, 2016 Press release - Non-regulatory Targovax presents ONCOS-102 scientific rationale at the European Society of Gene and Cell Therapy
October 17, 2016 Press release - Non-regulatory Targovax to Present at the ESGCT/ISSCR Stem Cells & Gene Therapy Symposium
September 19, 2016 Press release - Non-regulatory Targovax to present at Redeye’s Fight Cancer conference
August 25, 2016 Press release - Regulatory Targovax ASA: Interim Report second quarter and first half year 2016
August 17, 2016 Press release - Non-regulatory Targovax ASA: Completion of subsequent offering, registration of share capital increase
August 17, 2016 Press release - Non-regulatory Targovax ASA: Completion of subsequent offering, registration of share capital increase
August 15, 2016 Press release - Regulatory Targovax ASA: Invitation to second quarter 2016 results presentation Thursday 25 August
August 9, 2016 Press release - Non-regulatory Targovax ASA: Allocations to primary insiders in the subsequent offering
August 9, 2016 Press release - Non-regulatory Targovax ASA: Allocations to primary insiders in the subsequent offering
August 8, 2016 Press release - Non-regulatory Targovax ASA – Last day of the subscription period in the subsequent offering
August 8, 2016 Press release - Non-regulatory Targovax ASA – Last day of the subscription period in the subsequent offering
August 4, 2016 Press release - Non-regulatory Targovax ASA – The subscription period in the subsequent offering expires on Monday 8 August at 16:30 CET
August 4, 2016 Press release - Non-regulatory Targovax ASA – The subscription period in the subsequent offering expires on Monday 8 August at 16:30 CET
July 11, 2016 Press release - Non-regulatory Targovax ASA: Commencement of subscription period for the subsequent offering
July 8, 2016 Press release - Non-regulatory Targovax ASA: Publication of prospectus, listing on Oslo Axess and subsequent offering
July 7, 2016 Press release - Non-regulatory Targovax ASA: Completion of private placement, registration of share capital increase
July 6, 2016 Press release - Non-regulatory Targovax ASA: Extraordinary general meeting held, approval of private placement and subsequent offering
July 1, 2016 Press release - Non-regulatory Targovax recruits the first patient in a trial with the oncolytic virus ONCOS-102 in malignant pleural mesothelioma
July 1, 2016 Press release - Regulatory Targovax recruits the first patient in a trial with the oncolytic virus ONCOS-102 in malignant pleural mesothelioma
June 22, 2016 Press release - Non-regulatory Targovax ASA: Announcement of successful NOK 110 million private placement
June 21, 2016 Press release - Non-regulatory Targovax ASA: Update on bookbuilding for the private placement of NOK 100 – 130 million
June 20, 2016 Press release - Non-regulatory Targovax ASA: Contemplated private placement of NOK 100 – 130 million
June 9, 2016 Press release - Regulatory Targovax receives regulatory approval in Spain to conduct a clinical trial with its oncolytic virus ONCOS-102
June 7, 2016 Press release - Regulatory Targovax ASA: Patient recruitment for TG01 immuno-oncology trial completed
June 2, 2016 Press release - Regulatory Targovax receives approval in Australia to conduct a clinical trial with TG02 – an immunotheraphy treatment targeting RAS mutations
May 20, 2016 Press release - Non-regulatory Magnus Jaderberg, CMO of Targovax, has presented at a symposium by The Royal Swedish Academy of Engineering Sciences
May 9, 2016 Press release - Regulatory Targovax to present at BioEquity Europe and its first quarter 2016 results on May 11 – 12, 2016
May 9, 2016 Press release - Non-regulatory Targovax ASA: Registration of share capital increase following exercise of employee options
April 15, 2016 Press release - Non-regulatory Targovax ASA: Grant of restricted stock units to the Board of directors
April 14, 2016 Press release - Regulatory Targovax reports immune response with reduced number of TG01 vaccinations
April 14, 2016 Press release - Non-regulatory Resolution to increase the share capital in Targovax ASA in relation to exercise of employee options
March 15, 2016 Press release - Non-regulatory Targovax to present at forthcoming Life Science and Investor conferences
March 14, 2016 Press release - Regulatory Targovax to present at forthcoming Life Science and Investor conferences
March 10, 2016 Press release - Regulatory Targovax announces encouraging interim results with RAS specific peptide vaccine in resected pancreatic cancer
February 25, 2016 Press release - Regulatory CORRECTION: Targovax ASA: Invitation to Fourth Quarter 2015 Results Presentation
February 25, 2016 Press release - Regulatory Targovax ASA: Invitation to Fourth Quarter 2015 Results Presentation
February 2, 2016 Press release - Regulatory Targovax submits a study of its adenovirus based immune therapy ONCOS-102 to the regulatory authorities in Spain
